333 related articles for article (PubMed ID: 25647573)
1. Targeting carbonic anhydrase IX activity and expression.
Mahon BP; Pinard MA; McKenna R
Molecules; 2015 Jan; 20(2):2323-48. PubMed ID: 25647573
[TBL] [Abstract][Full Text] [Related]
2. Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs.
Thiry A; Supuran CT; Masereel B; Dogné JM
J Med Chem; 2008 Jun; 51(11):3051-6. PubMed ID: 18348513
[No Abstract] [Full Text] [Related]
3. Targeting tumor-associated carbonic anhydrase IX in cancer therapy.
Thiry A; Dogné JM; Masereel B; Supuran CT
Trends Pharmacol Sci; 2006 Nov; 27(11):566-73. PubMed ID: 16996620
[TBL] [Abstract][Full Text] [Related]
4. Design of a carbonic anhydrase IX active-site mimic to screen inhibitors for possible anticancer properties.
Genis C; Sippel KH; Case N; Cao W; Avvaru BS; Tartaglia LJ; Govindasamy L; Tu C; Agbandje-McKenna M; Silverman DN; Rosser CJ; McKenna R
Biochemistry; 2009 Feb; 48(6):1322-31. PubMed ID: 19170619
[TBL] [Abstract][Full Text] [Related]
5. N-β-glycosyl sulfamides are selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
Rodríguez OM; Maresca A; Témpera CA; Bravo RD; Colinas PA; Supuran CT
Bioorg Med Chem Lett; 2011 Aug; 21(15):4447-50. PubMed ID: 21723123
[TBL] [Abstract][Full Text] [Related]
6. Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target.
De Simone G; Supuran CT
Biochim Biophys Acta; 2010 Feb; 1804(2):404-9. PubMed ID: 19679200
[TBL] [Abstract][Full Text] [Related]
7. Efficient Expression and Crystallization System of Cancer-Associated Carbonic Anhydrase Isoform IX.
Leitans J; Kazaks A; Balode A; Ivanova J; Zalubovskis R; Supuran CT; Tars K
J Med Chem; 2015 Nov; 58(22):9004-9. PubMed ID: 26522624
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of carbonic anhydrase IX: a new strategy against cancer.
Winum JY; Scozzafava A; Montero JL; Supuran CT
Anticancer Agents Med Chem; 2009 Jul; 9(6):693-702. PubMed ID: 19601749
[TBL] [Abstract][Full Text] [Related]
9. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells.
Fiaschi T; Giannoni E; Taddei ML; Cirri P; Marini A; Pintus G; Nativi C; Richichi B; Scozzafava A; Carta F; Torre E; Supuran CT; Chiarugi P
Cell Cycle; 2013 Jun; 12(11):1791-801. PubMed ID: 23656776
[TBL] [Abstract][Full Text] [Related]
10. Pyridinium derivatives of 3-aminobenzenesulfonamide are nanomolar-potent inhibitors of tumor-expressed carbonic anhydrase isozymes CA IX and CA XII.
Akocak S; Güzel-Akdemir Ö; Kishore Kumar Sanku R; Russom SS; Iorga BI; Supuran CT; Ilies MA
Bioorg Chem; 2020 Oct; 103():104204. PubMed ID: 32891000
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions.
Chen F; Licarete E; Wu X; Petrusca D; Maguire C; Jacobsen M; Colter A; Sandusky GE; Czader M; Capitano ML; Ropa JP; Boswell HS; Carta F; Supuran CT; Parkin B; Fishel ML; Konig H
J Cell Mol Med; 2021 Dec; 25(24):11039-11052. PubMed ID: 34791807
[TBL] [Abstract][Full Text] [Related]
12. Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
Puccetti L; Fasolis G; Vullo D; Chohan ZH; Scozzafava A; Supuran CT
Bioorg Med Chem Lett; 2005 Jun; 15(12):3096-101. PubMed ID: 15908204
[TBL] [Abstract][Full Text] [Related]
13. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics.
McDonald PC; Winum JY; Supuran CT; Dedhar S
Oncotarget; 2012 Jan; 3(1):84-97. PubMed ID: 22289741
[TBL] [Abstract][Full Text] [Related]
14. Saccharin: a lead compound for structure-based drug design of carbonic anhydrase IX inhibitors.
Mahon BP; Hendon AM; Driscoll JM; Rankin GM; Poulsen SA; Supuran CT; McKenna R
Bioorg Med Chem; 2015 Feb; 23(4):849-54. PubMed ID: 25614109
[TBL] [Abstract][Full Text] [Related]
15. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
Lock FE; McDonald PC; Lou Y; Serrano I; Chafe SC; Ostlund C; Aparicio S; Winum JY; Supuran CT; Dedhar S
Oncogene; 2013 Oct; 32(44):5210-9. PubMed ID: 23208505
[TBL] [Abstract][Full Text] [Related]
16. Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
Moeker J; Peat TS; Bornaghi LF; Vullo D; Supuran CT; Poulsen SA
J Med Chem; 2014 Apr; 57(8):3522-31. PubMed ID: 24689792
[TBL] [Abstract][Full Text] [Related]
17. Carbonic anhydrase IX as a target for metastatic disease.
Gieling RG; Williams KJ
Bioorg Med Chem; 2013 Mar; 21(6):1470-6. PubMed ID: 23098607
[TBL] [Abstract][Full Text] [Related]
18. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain.
Zatovicova M; Jelenska L; Hulikova A; Csaderova L; Ditte Z; Ditte P; Goliasova T; Pastorek J; Pastorekova S
Curr Pharm Des; 2010; 16(29):3255-63. PubMed ID: 20819068
[TBL] [Abstract][Full Text] [Related]
19. Carbonic anhydrase IX inhibitors in cancer therapy: an update.
Supuran CT; Winum JY
Future Med Chem; 2015; 7(11):1407-14. PubMed ID: 26230880
[TBL] [Abstract][Full Text] [Related]
20. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII.
Guler OO; De Simone G; Supuran CT
Curr Med Chem; 2010; 17(15):1516-26. PubMed ID: 20166929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
